Aptose Biosciences Inc. logo
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
09 mars 2023 16h05 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Inc. logo
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
02 mars 2023 07h30 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Inc. logo
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
11 déc. 2022 09h00 HE | Aptose Biosciences, Inc.
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Third Quarter 2022
01 nov. 2022 16h01 HE | Aptose Biosciences, Inc.
─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent...
Aptose Biosciences Inc. logo
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
14 sept. 2022 07h30 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
13 sept. 2022 07h30 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability
12 sept. 2022 07h30 HE | Aptose Biosciences, Inc.
– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Second Quarter 2022
02 août 2022 16h01 HE | Aptose Biosciences, Inc.
─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete Remissions and Safety Across Three Dose Levels...
Aptose Biosciences Inc. logo
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
27 juil. 2022 07h30 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
19 juil. 2022 16h01 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...